Labiana Health (XMAD:LAB) Price-to-Tangible-Book : (As of Jun. 05, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Price-to-Tangible-Book?

As of today (2024-06-05), Labiana Health's share price is €2.36. Labiana Health's Tangible Book per Share of Dec. 2022 for the quarter that ended in Dec. 2022 was €-0.28. Hence, Labiana Health's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Labiana Health's Price-to-Tangible-Book or its related term are showing as below:

XMAD:LAB's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.31
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Labiana Health's share price is €2.36. Labiana Health's Book Value per Sharefor the quarter that ended in Dec. 2022 was €0.97. Hence, Labiana Health's P/B Ratio of today is 2.42.

Labiana Health Price-to-Tangible-Book Historical Data

The historical data trend for Labiana Health's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Price-to-Tangible-Book Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Price-to-Tangible-Book	-	-	12.60	-

Competitive Comparison of Labiana Health's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Labiana Health's Price-to-Tangible-Book falls into.

Labiana Health Price-to-Tangible-Book Calculation

Labiana Health's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2022 )
	=	2.36	/	-0.278
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Labiana Health Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Labiana Health's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Price-to-Tangible-Book

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.